PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug

Shares of Plus Therapeutics, Inc. (PSTV) were up a staggering 170.1% on March 20 after the company announced that the FDA has conditionally accepted — Reyobiq — as the new proprietary name for PSTV’s lead therapeutic candidate, rhenium Re186 obisbemeda.Plus Therapeutics’ request for a proprietary name review for Reyobiq must be submitted after the new drug application (NDA) is filed for the candidate.Per the company, going forward, all communications related to the USAN-adopted and INN-proposed rhenium Re18 ...